Manufacturing news briefs — stories you might have missed

Provaris Energy seeks swift restart to compressed hydrogen tank construction Australian green hydrogen developer Provaris Energy is working with secured lenders to have construction resume of its proprietary compressed hydrogen transport tank for the company’s proposed H2Neo carrier vessel. Earlier this month the company revealed the bankruptcy of Norwegian-based Prodtex Industri AS which operates the…

IDT and Sanofi to manufacture mRNA vaccines under development

Drug development company IDT Australia and pharmaceutical business Sanofi have signed an agreement for the good manufacturing practice (cGMP) manufacture of Sanofi’s mRNA vaccines now under development. The partners will collaborate to advance mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables filling facilities in Melbourne (pictured) in volumes needed for clinical trials…

Mesoblast gets FDA go ahead for pediatric drug

The US Food and Drug Administration has told biotechnology company Mesoblast that it now has sufficient clinical data to support a submission to approve the company’s remestemcel-L drug for treatment of pediatric patients. Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft versus host disease, and biologic-resistant inflammatory bowel…

Vaxxas needle free vaccines have great potential – study

Needle free vaccine delivery company Vaxxas‘s skin patch system is an attractive alternative to vaccine delivery via injection, according to a new study. Published in the journal Vaccine, the study said the company’s high-density microarray patch (HD-MAP) (pictured) was particularly attractive in a pandemic. Its’ use would alleviate the strain on healthcare systems by enabling…